Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13337173 | 1.00 | GSR (0.59) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL10046228 | 1.00 | GSR (0.59) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL20383848 | 0.98 | GSR (0.57) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL20388836 | 0.98 | GSR (0.57) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL13429506 | 0.98 | GSR (0.57) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL23762407 | 0.98 | GSR (0.57) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL12280588 | 0.93 | GSR (0.50) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL12278737 | 0.93 | GSR (0.50) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL17173859 | 0.93 | GSR (0.50) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL4761845 | 0.84 | GABRR1 (0.46) | GSRDPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911412-B2 | Derivatized chitosan polymers and methods of treating vascular disorders | SYNEDGEN, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | SYNEDGEN, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | SYNEDGEN, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | SYNEDGEN, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | SYNEDGEN, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2022174179-A9 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20230021050-A1 | COMPOSITIONS AND METHODS OF THEIR USE | SYNEDGEN, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11433092-B2 | Compositions and methods of use for wound healing | SYNEDGEN, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220160754-A1 | DERIVATIZED CHITOSAN POLYMERS AND METHODS OF TREATING VASCULAR DISORDERS | SYNEDGEN, INC. | 2022-05-26 | — | — | US | disclosed |
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2022-05-17 | — | — | US | disclosed |
| US-20120329751-A1 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | UNITED STATES GOVERNMENT | 2012-12-27 | — | — | US | disclosed |
| US-20120301408-A1 | ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | UNITED STATES GOVERNMENT | 2012-11-29 | — | — | US | disclosed |
| US-20120301408-A1 | ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | UNITED STATES GOVERNMENT | 2012-11-29 | — | — | US | disclosed |
| US-8119780-B2 | Chitosan-derivative compounds and methods of controlling microbial populations | SYNEDGEN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119780-B2 | Chitosan-derivative compounds and methods of controlling microbial populations | SYNEDGEN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2011028968-A1 | ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | SYNEDGEN, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010056927-A1 | CHITOSAN DERIVATIVES ALONE OR IN COMBINATION FOR THE TREATMENT OF MDR MICROBIAL INFECTIONS | SYNEDGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | UNITED STATES GOVERNMENT | 2007-12-06 | — | — | US | disclosed |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | UNITED STATES GOVERNMENT | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433092-B2 | Compositions and methods of use for wound healing | PARG, ARGLU1, AREG | GSR 3366/4885GNAI3 1127/4885GNAO1 1350/4885 |
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | ENTPD1, NME2, NME1 | GSR 2887/4885GNAI3 2512/4885GNAO1 332/4885 |
| US-20220160754-A1 | DERIVATIZED CHITOSAN POLYMERS AND METHODS OF TREATING VASCULAR DISORDERS | CHIA, CHI3L1, CHI3L2 | GSR 322/4885GNAI3 3119/4885GNAO1 2677/4885 |
| US-20230021050-A1 | COMPOSITIONS AND METHODS OF THEIR USE | ARG1, ARG2, FUT6 | GSR 286/4885GNAI3 1399/4885GNAO1 1639/4885 |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | ARG1, NRDC, CHIA | GSR 1727/4885GNAI3 2109/4885GNAO1 2306/4885 |
| US-20120329751-A1 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | CHIT1, ALG1, CSGALNACT1 | GSR 2761/4885GNAI3 1835/4885GNAO1 1832/4885 |
| US-20120301408-A1 | ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | CHIT1, ALG1, SI | GSR 1899/4885GNAI3 3903/4885GNAO1 3117/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | GSR 2449/4885GNAI3 2996/4885GNAO1 1420/4885 |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | CHIA, MMP8, CHIT1 | GSR 2485/4885GNAI3 3143/4885GNAO1 3506/4885 |
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | CHIT1, ALG1, CSGALNACT1 | GSR 2761/4885GNAI3 1835/4885GNAO1 1832/4885 |
| US-11911412-B2 | Derivatized chitosan polymers and methods of treating vascular disorders | CHIA, CHI3L1, CHI3L2 | GSR 322/4885GNAI3 3119/4885GNAO1 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.